Endocan与Galectin-3在微血管性心绞痛患者血清中的表达及其诊断价值

doi:10.3969/j.issn.1671-7171.2024.07.023

Abstract
Figure/Table
References
Related Citation (2)

Download: PDF (1258 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】To investigate the expression and diagnostic value of endothelial cell-specific molecule-1 (Endocan) and Galectin-3 in the serum of patients with microvascular angina (CMSA). 【Methods】A total of 87 CMSA patients treated at Yanji County People's Hospital were selected as the observation group, while 87 healthy individuals during the same period were selected as the control group. The relevant data and serum Endocan and Galectin-3 expression levels of the two groups were compared. Logistic multivariate regression analysis was used to analyze the influencing factors of CMSA. The diagnostic value of serum Endocan and Galectin-3 levels for CMSA was evaluated by the area under the receiver operating characteristic (ROC) curve (AUC). 【Results】The proportions of diabetes, hypertension, and high levels of fasting blood glucose, serum Endocan and Galectin-3 in the observation group were higher than those in the control group (P<0.05). Logistic multivariate regression analysis showed that increased levels of diabetes, hypertension, fasting blood glucose, serum Endocan, and Galectin-3 were risk factors for CMSA (P<0.05). ROC analysis showed that the AUC of serum Endocan, Galectin-3, and their combined detection for diagnosing CMSA were 0.731, 0.785, and 0.891, respectively. 【Conclusion】There is a high expression of serum Endocan and Galectin-3 in CMSA patients, and the diagnostic valueefficacy of serum Endocan and Galectin-3 in CMSA is high.

Key words： Microvascular Angina Galectin 3/BL

Received: 26 December 2023

PACS:

R541.4

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	CHEN Jing
	WANG Yongqiang
	LIU Meng

Cite this article:

CHEN Jing,WANG Yongqiang,LIU Meng. Expression and Diagnostic Value of Endocan and Galectin-3 in Serum of Patients with Microvascular Angina[J]. JOURNAL OF CLINICAL RESEARCH, 2024, 41(7): 1041-1043.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2024.07.023 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2024/V41/I7/1041

[1] 赵外荣,张静,施雯婷,等. 冠状动脉微血管疾病的发病机制及国内外治疗研究进展[J].世界中西医结合杂志,2023,18(3):624-630.
[2] 窦敏,单迎光,许建威,等. 纤维蛋白原/白蛋白比值与冠状动脉微血管疾病的相关性分析[J].中国心血管杂志,2023,28(1):29-33.
[3] 石川,田佳文,干倩,等. 动态99 m Tc-sestamibi CZT-SPECT评价老年胸痛患者冠状动脉微血管功能障碍的临床特征[J].老年医学与保健,2024,30(2):283-289.
[4] 王晓玲,张立杰,肖四海,等. 慢性心力衰竭患者循环Endocan水平与心功能相关性及其对心血管主要终点事件的影响[J].中国循证心血管医学杂志,2023,15(3):302-305.
[5] 刘聪,赵文超,赵立月. 急性冠脉综合征患者血清Gal-3、TPOAb、TP53表达及PCI术后心血管事件的危险因素分析[J].中国循证心血管医学杂志,2023,15(8):1004-1007.
[6] 中华医学会心血管病学分会,中华心血管病杂志编辑委员会. 缺血伴非阻塞性冠状动脉疾病诊断及管理中国专家共识[J].中华心血管病杂志,2022,50(12):1148-1160.
[7] 张艳达,隋汝杰,赵健,等. 冠状动脉微循环障碍:非阻塞性冠心病潜在发病机制[J].第二军医大学学报,2020,41(3):315-320.
[8] 潘小玉,张再伟. 微血管性心绞痛诊治的最新进展[J].中西医结合心脑血管病杂志,2020,18(22):3803-3805.
[9] 马乔炎,张平. 冠心病病人血浆中相关炎症因子水平及其与TIPE2的关系研究[J].实用老年医学,2019,33(6):569-572.
[10] QAYYUM A A, JOSHI F R, LUND L D, et al.Vascular endothelial growth factor therapy in ischaemic heart disease[J].Ugeskr Laeger,2020,182(44):344-347.
[11] 董丹萍,谢芳,热衣拉?买买提,等. 血清AngⅡ、apoB/apoA-1联合endocan对高血压患者并发冠心病的预测价值[J].分子诊断与治疗杂志,2023,15(7):1238-1242.
[12] 刘闯,闫佩佩,陈雅丽,等. Gal-3、SFRP5、H-FABP联合检测对冠心病患者预后评估的临床价值[J].中国循证心血管医学杂志,2023,15(1):102-105.
[13] 郑国坤,何贵新,冯雨菲,等. 基于半乳糖凝集素3与冠状动脉病变程度相关系数的Meta分析[J].中国动脉硬化杂志,2022,30(7):611-617.
[14] 顾淑君,张秋伊,周正元. 2型糖尿病人群中高尿酸血症与心血管病死亡风险的队列研究[J].实用预防医学,2021,28(4):435-438.
[15] 王小溪,赵红丽,张晓丹,等. 冠状动脉慢血流型心绞痛患者血清sCD40L、endocan水平及临床意义[J].检验医学与临床,2022,19(3):385-388.